Clinical Trial Update: Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive [Phase 1]

View source ↗

Summary

Phase 1 study of SU011248 in combination with docetaxel and trastuzumab in advanced HER-2 positive breast cancer; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• SU011248
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2012-10-30